News Sanofi grabs Chinese rights to Arrowhead rare disease drug Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.
News Lilly's appeal unlocks EU approval of Alzheimer's drug Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.
News FDA clears Ionis drug as first therapy for rare disease FCS Ionis Pharma's Tryngolza (olezarsen) has become the first FDA-approved drug therapy for adults with rare disease familial chylomicronaemia syndrome.
News As Ebola deaths climb, search begins for vaccine The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola and fast-track clinical trials.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.